Cencora (NYSE:COR – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13, FiscalAI reports. The business had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company earned $4.00 earnings per share.
Here are the key takeaways from Cencora’s conference call:
- Fiscal 2026 adjusted EPS guidance was raised to $17.75–$17.95 from $17.70–$17.90, supported by strong year-to-date execution and $1 billion of share repurchases.
- Third-quarter adjusted operating income increased 17% and adjusted EPS rose 12%; U.S. Healthcare Solutions benefited from strong specialty utilization and better-than-expected performance at OneOncology and RCA.
- International Healthcare Solutions operating income grew 21% as European distribution, World Courier, and European 3PL delivered strong results, while MWI Animal Health also performed ahead of expectations.
- Management highlighted continued long-term opportunities in Part B biosimilars, MSO expansion, clinical-trial services, AI-enabled demand forecasting, and specialty logistics, while emphasizing that OneOncology’s integration and platform expansion remain in relatively early stages.
- Higher debt from the OneOncology acquisition lifted quarterly net interest expense by $59 million year over year, and management expects the potential MWI-Covetrus transaction to create an estimated $0.35 fiscal 2027 EPS headwind if it closes around midyear; stronger-dollar effects are also reducing international revenue growth.
Cencora Stock Performance
Shares of COR stock traded down $2.27 during trading hours on Friday, reaching $322.74. 546,059 shares of the company’s stock were exchanged, compared to its average volume of 1,539,051. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.59. Cencora has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a market cap of $62.79 billion, a P/E ratio of 23.94, a price-to-earnings-growth ratio of 1.76 and a beta of 0.57. The company’s 50 day moving average is $292.86 and its two-hundred day moving average is $314.37.
Cencora Announces Dividend
Analysts Set New Price Targets
COR has been the topic of several recent research reports. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Wells Fargo & Company dropped their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Morgan Stanley reiterated an “overweight” rating and issued a $346.00 price objective on shares of Cencora in a report on Friday. Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Finally, Robert W. Baird set a $370.00 target price on Cencora in a research report on Thursday. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $368.92.
Check Out Our Latest Research Report on Cencora
Insiders Place Their Bets
In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.38% of the stock is owned by insiders.
Hedge Funds Weigh In On Cencora
A number of institutional investors have recently modified their holdings of COR. Compound Planning Inc. grew its stake in shares of Cencora by 28.1% during the 4th quarter. Compound Planning Inc. now owns 1,505 shares of the company’s stock valued at $508,000 after buying an additional 330 shares during the period. Axxcess Wealth Management LLC grew its holdings in shares of Cencora by 69.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 16,721 shares of the company’s stock worth $5,648,000 after purchasing an additional 6,853 shares during the period. Note Advisors LLC increased its position in Cencora by 9,906.0% during the 4th quarter. Note Advisors LLC now owns 73,244 shares of the company’s stock worth $24,738,000 after purchasing an additional 72,512 shares in the last quarter. Strive Financial Group LLC purchased a new position in Cencora in the fourth quarter valued at approximately $2,636,000. Finally, First Commonwealth Financial Corp PA lifted its position in Cencora by 5.0% during the fourth quarter. First Commonwealth Financial Corp PA now owns 3,425 shares of the company’s stock valued at $1,157,000 after buying an additional 163 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Cencora declared that its board has initiated a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.
Cencora Company Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
